Review of Tests for Monitoring Doxorubicin-lnduced Cardiomyopathy

Oncology (Switzerland)

Volumn 53, Issue 6, 1996, Pages 461-470

  Ganz, William I ^a,b   Sridhar, Kasi S ^a,b   Ganz, Susan S ^c   Gonzalez, Rigoberto ^a,b   Chakko, Simon ^a,b   Serafini, Aldo ^a,b  

^a Department of Radiology ^*  (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c Universal Clin Laboratories Inc   (United States)

Author keywords

Cardiotoxicity; Doxorubicin; Ejection fraction; Left ventricular; Peak filling rate

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; INDIUM 111; MONOCLONAL ANTIBODY; RADIOISOTOPE;

ADRENERGIC NERVE CELL; ALGORITHM; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DIASTOLE; ECHOCARDIOGRAPHY; EXERCISE TEST; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCREENING TEST;

ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; DOXORUBICIN; DRUG MONITORING; HEART; HUMANS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 0029964861     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227621     Document Type: Article

References (62)

1. Wortman JE, Lucas VS, Pharm BS, Schuster E, Thiele D, Logue GL: Sudden death during doxorubicin administration, Cancer 1979:44: 1588-1591.
2. Bristow MR, Mason JW, Billingham ME, Daniels JR: Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization, Ann Intern Med 1978;88:168-175.
3. Manusco L, Marchi S, Canonico A: Dynamic left ventricular outflow obstruction and myocardial infarction following doxorubicin administration in a woman affected by unsuspected hypertrophic cardiomyopathy, Cancer Treat Rep 1985:69:241-244.
4. Harrison DT, Sanders LA: Pericarditis in a case of early daunorubicin cardiomyopathy, Ann Intern Med 1976:85:339-340.
5. Bristow MR, Billingham ME, Mason JW, Daniels JR: Clinical spectrum of anthracyclinc antibiotic cardiotoxicity, Cancer Treat Rep 1978: 62:873-879.
6. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, Canetta R, Castallani R, Villa E, Gallagher CG, Melchner H, Hayat M, Ribaud P, Wasch G, Mattsson W, Heinz R, Waldncr R, Kolaric K, Buchner R, Ten Bokkcl-Huyninck W, Perevodchikova NI, Manziuk LA, Scnn HJ, Mayr AC: Adriamycin cardiotoxicity: A survey of 1273 patients, Cancer Treat Rep 1979:63:827-834.
7. VonHof TDD, Layard MW, Basa P, Davis HL, VonHoff AL, Rozenweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure, Ann Intern Med 1979:91:715-717.
8. Blum RH, Carter SK: Adriamycin: A new anti-cancer drug with significant clinical activity, Ann Intern Med 1974;80:249-259.
9. Sridhar KS, Holland JF, Brown JC, Cohen JM, Ohnuma T: Doxorubicin plus cis-platin in the treatment ofapudomas, Cancer 1985:55:2634-2637.
10. Sridhar KS, Chahinian AP, Schwartz IS: Tongue mctastascs from undifferentiated small cell (oat cell) lung cancer, J Fla Med Assoc 1985:72:428-430.
11. Kristian A, Sridhar KS, Davila E, Vogel C, Stemheim W: Patterns of anthracyclinc modulation in human tumor cells, Cytometry 1987; 8:306-314.
12. Olson RD, Mushlin PS: Doxorubicin cardio-toxieity: Analysis of prevailing hypotheses, Rev Am Soc Exp Biol 1990:4:3076-3086.
13. Weiss AJ, Manthel RW, Fletcher WS: Experience with the use of adriamycin in combination with the other anti-cancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity, Cancer 1977;40:2046-2052.
14. Lctha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivicso M, Rasmussen SL, Blu-menschein GR, Freireich EJ: Reduction of doxorubicin cardiotoxicity by prolonged continuous infusion, Ann Intern Med 1982;96: 133-139.
15. O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, Grumct GN, Salmon SE, Moon TE, Hoogstraten B: Dose response evaluation of adriamycin in human neoplasia, Cancer 1977:39:1940-1948.
16. Seifert CF, Nesser ME, Thompson DF: Dexra-zoxane in the prevention of doxorubicin-induced cardiotoxicity, Ann Pharmacothcr 1994; 28:1063-1072.
17. Hochstcr H, Wasserheit C, Speyer J: Cardiotoxicity and cardioprotcction during chemotherapy, CurrOpin Oncol 1995;7:304-309.
18. Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, Duffy T, Schwartz P, Gottschalk A, Zaret BE: Serial assessment of doxorubicin cardiotoxicity with quantitative angiocardiography, N Engl J Med 1979:300: 278-283.
19. Duckart G, Rosncr L, Henry D: Comparative cardiotoxicity of nitroxantrone vs doxorubicin, Proc Soc Clin Oncol 1996;5:48.
20. Sridhar KS, Sarny TSA, Koch G, Agarwal RP, Duncan RC, Ganz WI, Benedetto P, Feun LG, Savaraj N, Gross J, Krishan A, Zubrod CG: Phase I study of 4'-0-tctrahydropyranyladria-mycin; in Kuemmerle HP (cd): Advances in Experimental and Clinical Chemotherapy, Munich, Ecomed, 1988, pp 11-26.
21. Dresdale A, Bonow RO, Wesley R, Palntcri ST, Barr L, Mathison D, D’Angelo T, Rosenberg SA: Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsur-gical adjuvant treatment of patients with soft tissue sarcomas, Cancer 1983;52:51-60.
22. Gottdicner JS, Appelbaum FR, Ferrans VJ, Dcisscroth A, Ziegler J: Cardiotoxicity associated with high dose cyclophosphamide therapy, Arch Intern Med 1981;141:758-763.
23. Chakko S, Woska D, Martinez H, De Marchena ED, Futterman L, Kessler KM, Myerburg RS: Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: Conflicting results may lead to inappropriate care, Am J Med 1991:90:353-356.
24. Haq MM, Legha SS, Choski J, Hortobagyi GN, Benjamin RS, Ewer M, Ali M: Doxorubicin-induced heart failure in adults, Cancer 1985; 56:1361-1365.
25. Friedman MJ, Ewy GA, Jones SE, Cruze D, Moon TA: 1-year follow up of cardiac status after Adriamycin therapy, Cancer Treat Rep 1979:63:1809-1816.
26. Ritchie JL, Singer JW, Thorning D, Sorensen SG, Hamilton GW: Anlhracycline cardiotoxicity: Clinical and pathologic outcomes assessed by radionuclide ejection fraction, Cancer 1980; 46:1109-1116.
27. Gottdiener JS, Mathison DJ, Borer JS, Bonow RO, Myers CE, Barr LH, Schwartz DE, Bacha-rach SL, Green MV, Rosenberg SA: Doxorubicin cardiotoxicity: Assessment of late left ventricular dysfunction by radionuclide cineangiography, Ann Intern Med 1981;94:430-435.
28. Saini J, Rich MW, Lyss AP: Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity, Ann Intent Med 1987; 106:814-816.
29. Schwartz RG, McKenzie WB, Alexander J, Sager P, D’Souza A, Manatunga A, Schwartz PE, Berger HJ, Setaro J, Surkin L, Wackers FJ, Zaret BL: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: Seven-year experience using radionuclide angiocardiography, Am J Med 1987:82: 1109-1118.
30. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity, Cancer 1973:32:302-314.
31. Mason JW, Bristow MR, Billingham ME, Daniels JR: Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man, superiority of histopathologic assessment using endomyocardial biopsy, Cancer Treat Rep 1978:62:857-864.
32. Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA: Efficacy and cost of cardiac monitoring in patients receiving doxorubicin, Cancer 1982;50:32-41.
33. Wackers FJ, Berger HJ, Johnstone DE, Goldman L, Reduto LA, Langou RA, Gottschalk A, Zaret BL: Multiple gated cardiac blood pool imaging for left ventricular ejection fraction: Validation of the technique and assessment of variability, Am J Cardiol 1979:43:1159.
34. Oyamadca H, Yamada Y, Nomura E, Nakani-shi Y, Abe S, Horikoshi N, Ogihara A, Aiba K, Inamoto Y: Reliability of data obtained by radionuclide angiocardiography in follow-up studies with special reference to intra- and interobserver variations, Nucl Med Commun 1994;15:690-696.
35. Wexlcr JP, Rabinowitz AM, Ganz WI, Yee C, Blaufox MD: Automated batch processing of radionuclide angiograms, J Nucl Med 1980:21: 72.
36. Ganz WI, Wexlcr JP, Brenner AL, Bontemps R, Steingart R, Blaufox MD: Variabilityof resting gated ejection fraction, J Nucl Med 1980; 21:63.
37. Slutsky R, Karliner J, Battler A, Pfisterer M, Swanson S, Ashbum W: Reproducibility of ejection fraction and ventricular volume by gated radionuclide angiography after myocardial infarction, Radiology 1979;132:155-159.
38. Ganz WI, Wexlcr JP, Rabinowitz AM, Brenner AL, Steingart R, Blaufox MD: Methods of improving the precision of left ventricular volume and ejection fraction determination, J Nucl Med 1980:21:48.
39. Ganz WI, Sridhar KS, Forness T: Detection of early anthracyclinc cardiotoxicity by monitoring peak filling rate, Am J Clin Oncol 1993:16: 109-112.
40. Keogh AM, Eberl S, Yeatcs MG, Freund J, Hickic JB, Esmore DS, Spratt PM, Chang VP: Reproducibility of radionuclide left ventricular ejection fraction in patients awaiting cardiac transplantation, Clin Nucl Med 1990; 15:25-28.
41. Ganz WI, Gentili A, Miller T, Chahinc R, Scra-fini A: Use of peak filling rate (PFR) to detect early anthracycline cardiotoxicity, J Nucl Med 1986:27:1796.
42. Nachitz JE, Yeshurun D, Abrahamson J: Arterial occlusive disease in occult cancer, Am Heart J 1992;124:738-745.
43. Nachitz JE, Yeshurun D, Abrahamson J, Eldar S, Chouri H, Kedar S, Weinberger M, Golham-mer EG, Lev L, Egoz N: Ischemic heart disease precipitated by occult cancer, Cancer 1992:69: 2712-2720.
44. Dey HM, Kassamali H: Radionuclide evaluation of doxorubicin cardiotoxicity, The need for cautious interpretation, Clin Nucl Med 1988;13:565-568.
45. Druck MN, Gusenchyn WH, Evans WK, Got-lieb A, Sriglcy JR, Bar-Shlomo B, Feigln DH, McEwan P, Silver MD, Millband L, Winter K, Hilton JD, Jablonsky G, Morch JE, McLaughlin P: Radionuclide angiography and radionuclide case endomycardial biopsy in the assessment of doxorubicin cardiotoxicity, Cancer 1984:53:1667-1674.
46. Young RC, Ozols RF, Myers CE: The anthracycline antineoplastic drugs, N Engl J Med 1981;305:139-153.
47. Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT: Alterations in left ventricular function with doxorubicin therapy, J Am Coll Cardiol 1987;9:184-188.
48. Jain KK, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V, Schwartz W, Cassidy C, Pctroni GR, Young CW, Wittes RE: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer, J Clin Oncol 1985;3:818-826.
49. Miller TR, Grossman SJ, Schectman KB, Biel-lo DR, Ludbrook PA, Ehsani AA: Left ventricular diastolic filling and its association with age, Am J Cardiol 1986;58:531-535.
50. Dougherty AH, Naccarelli GV, Gray EL, Hicks CH, Goldstein RA: Congestive heart failure with normal systolic function, Am J Cardiol 1984;54:778-782.
51. Soufcr R, Wohlgclemter D, Vita NA, Amu-chestgui M, Sostman HD, Berger HJ, Zaret BL: Intact systolic left ventricular function in clinical congestive heart failure, Am J Cardiol 1985: 55:1032-1036.
52. McKillop JH, Bristow MR, Goris ML, Bil-lingham ME, Bockemiihl K: Sensitivity and specificity of ejection fractions in doxorubicin cardiotoxicity, Am Heart J 1983; 106:1048- 1056.
53. Gibbons RJ, Lee KL, Cobb F, Jones RH: Ejection fraction response to exercise in patients with chest pain and normal coronary arteriograms, Circulation 1981;64:952-957.
54. Hurwitz RA, Siddiqui A, Caldwell RL, Weet-man RM, Girod DA: Assessment of ventricular function in infants and children: Response to dobutamine infusion, Clin Nucl Med 1990; 15: 556-559.
55. Jain D, Zaret BL: Antimyosin cardiac imaging - Will it play a role in detection of doxorubicin cardiotoxicity? J Nucl Med 1990:31:1970-1974.
56. Estorch M, Carrio I, Berna L, Martinez-Dunck-er C, Alonso C, Germa JR, Ojeda B: Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer, J Nucl Med 1990:31:1965-1970.
57. Carrio I, Estorch M, Berna L, Germa JR, Alonso C, Ojeda B, Andres L, Lopez-Pousa A, Mar-tincz-Dunckcr C, Torres G: Assessment of an-thracycline-induced myocardial damage by quantitative indium-111 myosin specific monoclonal antibody studies, Eur J Nucl Med 1991;18:806-812.
58. Isobe M, Haber E, Khaw BA: Early detection of rejection and assessment ofcyclosporine therapy by ln-111-antimyosin imaging in mouse heart allografts, Circulation 1991:84:1246-1255.
59. Hiroe M, Ohta Y, Fujita N, Nagata M, Toyoza-ki T, Kusakabe K, Sekiguchi M, Marunto F: Myocardial uptake of 111-In monoclonal antimyosin Fab in detecting doxorubicin cardiotoxicity in rats: Morphological and hemodynamic findings, Circulation 1992:86:1965- 1972.
60. Wakasagi S, Wade A, Hascgawa Y, Nakano S, Shibata N: Detection of abnormal adrenergic neuron activity in Adriamycin induced cardiomyopathy with iodine-125-metaiodobenzyl-guanidinc, J Nucl Med 1992:33:208-214.
61. Bristow MR, Mason JW, Billingham ME, Daniels JR: Dose effect and structure function relationships in doxorubicin cardiomyopathy, Am Heart J 1981:102:704-708.
62. Isner JM, Ferrans VJ, Cohen SR, Witkind BG, Virniani R, Gottdiener JS, Beck JR, Roberts WC: Clinical and morphological cardiac findings after anthracycline chemotherapy: Analysis of 64 patients studied at necropsy, Am J Cardiol 1983:51:1167-1174.